Contact:
Shlomit Boguslavsky, Clinical Research Coordinator
416-586-4800 x 8351
Shlomit.Boguslavsky@SinaiHealth.ca

Primary Investigator: Dr. Hillary Steinhart
Enrolment: Ongoing

Mount Sinai Hospital is participating in a research study to understand the safety and effectiveness of an investigational medication for treating Crohn’s Disease.
This mediation is given orally (by mouth).

We are looking for individuals:

• With Crohn’s Disease.
• Experiencing symptoms related to their Crohn’s Disease.
• Have previously and/or currently not responded to one of the following standard treatments:
  • Corticosteroids (e.g. Prednisone, Budesonide)
  • Immunosuppressants (e.g., Imuran, Methotrexate, 6-MP)
  • Biologic Therapy (e.g., Remicade, Humira, Stelara)   

This study will last up to 4.5 years. Your Crohn’s Disease will be assessed and, if eligible, participants will be randomized in a 2:1 ratio to receive study medication or placebo ("dummy" drug). If your Crohn’s Disease has not improved by week 12 of the study, you may be eligible for the open-label (no placebo) portion of the study. Reimbursement will be provided for study-related travel expenses.